Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, Van Dao T, Kang YK, Thungappa SC, Kudo M, Sangro B, Kelley RK, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Azevedo S, Reig M, Assenat E, Yarchoan M, He AR, Makowsky M, Gupta C, Negro A, Chan SL.
Lau G, et al. Among authors: negro a.
J Hepatol. 2024 Jul 31:S0168-8278(24)02424-3. doi: 10.1016/j.jhep.2024.07.017. Online ahead of print.
J Hepatol. 2024.
PMID: 39089633
Free article.